Alzheimer's Association Statement on CMS Announcement of Registry for Access to FDA-Approved Alzheimer's Treatments
CHICAGO, June 1, 2023 /PRNewswire/ -- The Alzheimer's Association recognizes that the Centers for Medicare & Medicaid Services (CMS) has announced their conceptual approach to fulfill their commitment to immediate coverage of Food and Drug Administration (FDA) traditionally approved Alzheimer's treatments. We continue to believe that registry as a condition of coverage is an unnecessary barrier.
Registries are important tools to gather much needed real-world evidence to transform and improve patient care. But, registries should not be a requirement for coverage of a FDA-approved treatment.
We look forward to learning more details from CMS and we are hopeful for the future of health care access for our constituents. However, we remain concerned that the requirement of clinicians to register and enter data will create unnecessary hurdles.
In its announcement CMS said it will have a nationwide CMS-facilitated portal and other future registries may also qualify. Additional information about the data submission, registry requirements and details about how patients and physicians can enroll is still needed.
About the Alzheimer's Association®
The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-association-statement-on-cms-announcement-of-registry-for-access-to-fda-approved-alzheimers-treatments-301840304.html
SOURCE Alzheimer's Association
Upcoming Life Sciences Events
- September 2023
- Barcelona: BioSpain 2023
- October 2023
- New York City: BioFuture
Latest company news
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China